Pharmacologic class (EPC) · 4 drug pages

Antiparasitic: adverse event reports filed with FDA

4,517 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

4,517
reports across the class: 0% of all reports; 363
reports, 12 months to June 2026: 286 in the 12 months before; 55.8%
marked serious by the reporter: 57.4% across all reports; 4
drugs with a page: brand and generic names counted separately

Antiparasitic is a pharmacologic class (an FDA Established Pharmacologic Class) with 4 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 4,517 adverse event reports received by FDA, 0% of the database, from January 2004 to June 2026.

363 reports arrived in the 12 months to June 2026, up 27% from 286 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 55.8% of the class's reports are marked serious, 8.7% record death among the outcomes and 36.4% record hospitalisation, as reported.

Across the class the reactions recorded most often are drug ineffective (14.6%), headache (12%) and asthenia (11.5%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
StromectolIvermectin	brand	1,767	19	81.3%	Asthenia
Ivermectin	generic	1,577	337	64%	Drug ineffective
SoolantraIvermectin	brand	657	5	10%	Erythema
SkliceIvermectin	brand	516	2	1.4%	Drug ineffective

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Drug ineffectivethe medicine did not work as expected14.6%659
Headachehead pain12%543
Astheniaweakness or lack of energy11.5%521
Pyrexiafever9%408
Product use in unapproved indicationused for a purpose not on the label8.9%404
Off label useused for a purpose or in a way not on the label7.3%328
Pruritusitching6.7%301
Ocular hyperaemiaa red eye5.4%242
Coma5.2%237
Conjunctival haemorrhage5.2%234
Vertigoa spinning sensation4.6%207
Erythemaskin redness4.3%194
Back painback pain4.3%193
Diarrhoealoose or frequent stools4.3%193
Vomitingbeing sick3.2%145
Arthralgiajoint pain3.1%140
Gait disturbancedifficulty walking3%134
Encephalopathy2.9%132
Rosacea2.8%128
Urinary incontinenceleaking urine2.8%128
Depressed level of consciousness2.5%115
Rashskin rash2.5%112
Skin burning sensationburning skin2.4%110
Condition aggravatedthe condition being treated got worse2%89
Myalgiamuscle pain2%89

Solid bar: share of all class reports. Hollow bar: the median share across the 4 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death8.7%392

Life-threatening3.9%177

Hospitalisation (initial or prolonged)36.4%1,646

Disability2.5%114

Congenital anomaly0.3%13

Other serious21.9%988

Not serious44.2%1,997

Patient age

Under 20.3%14

2 to 112.5%114

12 to 172.5%114

18 to 4424%1,082

45 to 6421.1%955

65 to 747.8%352

75 and over8.3%376

Age not given33.4%1,510

Who reported

Physician36.2%1,635

Pharmacist4.9%221

Other health professional22.5%1,017

Lawyer0.1%3

Consumer or non-health professional33.7%1,523

Not given2.6%118

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Antiparasitic reports

Which drugs are in the Antiparasitic class on this site?

Stromectol, Ivermectin, Soolantra and Sklice. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

4,517 reports through June 2026, 363 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

drug ineffective (14.6%), headache (12%), asthenia (11.5%), pyrexia (9%) and product use in unapproved indication (8.9%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.